Parental vaccination to reduce measles immunity gaps in Italy.
epidemiology
global health
immunity gaps
mandatory vaccination
mathematical model
measles elimination
parental vaccination
school entry vaccination
virus
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
03 09 2019
03 09 2019
Historique:
received:
07
01
2019
accepted:
07
08
2019
entrez:
4
9
2019
pubmed:
4
9
2019
medline:
20
2
2020
Statut:
epublish
Résumé
High-income countries are experiencing measles reemergence as the result of suboptimal vaccine uptake and marked immunity gaps among adults. In 2017, the Italian Government introduced mandatory vaccination at school entry for ten infectious diseases, including measles. However, sustainable and effective vaccination strategies targeting adults are still lacking. We use a data-driven model of household demography to estimate the potential impact on future measles epidemiology of a novel immunization strategy, to be implemented on top of the 2017 regulation, which consists of offering measles vaccine to the parents of children who get vaccinated. Model simulations suggest that the current vaccination efforts in Italy would not be sufficient to interrupt measles transmission before 2045 because of the frequency of susceptible individuals between 17 and 44 years of age. The integration of the current policy with parental vaccination has the potential to reduce susceptible adults by 17-35%, increasing the chance of measles elimination before 2045 up to 78.9-96.5%.
Identifiants
pubmed: 31477199
doi: 10.7554/eLife.44942
pii: 44942
pmc: PMC6721460
doi:
pii:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019, Marziano et al.
Déclaration de conflit d'intérêts
VM, PP, FT, AM, MA, SM No competing interests declared
Références
Pediatr Infect Dis J. 2002 Aug;21(8):763-8
pubmed: 12192166
Expert Rev Vaccines. 2014 Feb;13(2):277-83
pubmed: 24350731
Science. 2000 Jan 28;287(5453):667-70
pubmed: 10650003
J Math Biol. 1990;28(4):365-82
pubmed: 2117040
Lancet Infect Dis. 2018 Jan;18(1):26-27
pubmed: 29303734
J R Soc Interface. 2010 Jun 6;7(47):873-85
pubmed: 19892718
BMC Med. 2019 May 17;17(1):86
pubmed: 31096986
Sci Rep. 2017 Sep 26;7(1):12324
pubmed: 28951551
J Infect Dis. 2017 Dec 5;216(10):1183-1184
pubmed: 29040599
J R Stat Soc Ser A Stat Soc. 2012 Apr;175(2):491-511
pubmed: 22879704
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
Vaccine. 2007 May 4;25(18):3574-80
pubmed: 17300858
Proc Biol Sci. 2007 Feb 22;274(1609):599-604
pubmed: 17476782
BMC Public Health. 2007 Jun 08;7:99
pubmed: 17555601
Expert Rev Vaccines. 2019 Jan;18(1):5-13
pubmed: 30501454
Euro Surveill. 2018 May;23(22):
pubmed: 29871721
J Theor Biol. 2004 Jul 7;229(1):119-26
pubmed: 15178190
N Engl J Med. 2016 Oct 6;375(14):1392-1393
pubmed: 27705259
BMJ. 2018 Apr 23;361:k1771
pubmed: 29685945
Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):146-58
pubmed: 26499433
J Infect Dis. 2003 May 15;187 Suppl 1:S158-63
pubmed: 12721908
Lancet Infect Dis. 2017 Oct;17(10):1013-1014
pubmed: 28807626
Vaccine. 2008 Aug 12;26(34):4403-9
pubmed: 18585420
PLoS Comput Biol. 2011 Sep;7(9):e1002205
pubmed: 21980281
Nature. 2004 Dec 16;432(7019):904-6
pubmed: 15602562
Epidemiol Infect. 1995 Oct;115(2):315-23
pubmed: 7589271
Vaccine. 2018 Feb 1;36(6):779-787
pubmed: 29325822
Euro Surveill. 2010 Apr 29;15(17):
pubmed: 20460082
Euro Surveill. 2017 Sep 14;22(37):
pubmed: 28933342
Proc Biol Sci. 2014 Jan 08;281(1777):20132676
pubmed: 24403333
Lancet Infect Dis. 2017 Oct;17(10):1089-1097
pubmed: 28807627
PLoS Comput Biol. 2012;8(9):e1002673
pubmed: 23028275